Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02598960 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
A Phase 1 study of Solid Tumors, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 295
- Enrollment target
- 20
- Study locations
NCT02598960: Completed Phase 1 study of Solid Tumors, sponsored by Bristol-Myers Squibb.
NCT02598960 is a Phase 1 study of Solid Tumors that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 295 participants, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02598960, a Phase 1 study of Solid Tumors, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 295 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tumor-shrinking ability of experimental medication BMS-986156, when given by itself or in combination with nivolumab in patients with solid cancers that are advanced or cancers that have spread.
Primary Outcome
Number of participants with all cause adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, and number of participant deaths. AEs and laboratory values will be graded according to the NCI CTCAE version 4.03.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG BMS-986156
Study Locations (20)
Other
- Local Institution - 0012 - Ghent
- Local Institution - Paris
- Institut Claudius Regaud - Toulouse
- Institut Gustave Roussy - Vlllejuif
- Local Institution - Bonn
- Local Institution - Freiburg im Breisgau
- Local Institution - Würzburg
New South Wales
- Liverpool Cancer Therapy Center - Liverpool
- Local Institution - Westmead
Alabama
- University Of Alabama At Birmingham - Birmingham
California
- UCSD Moores Cancer Center - La Jolla
Georgia
- Emory University - Atlanta
Ohio
- The Ohio State University - Columbus
Oregon
- Providence Portland Medical Center - Portland
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2015-10-14 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 1 |
What the finished NCT02598960 record still lists
NCT02598960 is an interventional study that assigns participants to a tested intervention. The registered 295 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT02598960 names 20 study sites across 13 states, led by Other, New South Wales, Alabama.
Frequently Asked Questions
What is clinical trial NCT02598960 about?
NCT02598960 is a clinical study titled "An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.". The purpose of this study is to evaluate the safety and tumor-shrinking ability of experimental medication BMS-986156, when given by itself or in combination with nivolumab in patients with solid cancers that are advanced or cancers that have spread.
What is the current status of trial NCT02598960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 295 participants. The study started on 2015-10-14. Estimated completion is 2019-12-16.
What conditions does trial NCT02598960 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT02598960?
The interventions under investigation include: Nivolumab (DRUG), BMS-986156 (DRUG).
Who is sponsoring clinical trial NCT02598960?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02598960 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02598960's enrollment target sits among peer trials
295 17th of 125 higher than 109 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05201781 · 295 participants · Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- NCT06004245 · 295 participants · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- NCT06494111 · 295 participants · Phase 2
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
- NCT07020221 · 295 participants · Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI